Nahdi Medical Company (4164.SR) — Financial statements
Income statement, balance sheet, and cash flow for Nahdi Medical Company — annual and quarterly history with growth and margin analysis.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 10,213↑8.1% | 9,446↑8.4% | 8,714↑1.1% | 8,616↑6.8% | 8,066 | |
| Cost of Revenue | 6,408↑8.4% | 5,914↑12.0% | 5,278↑3.6% | 5,095↑7.0% | 4,762 | |
| Gross Profit | 3,806↑7.7% | 3,533↑2.8% | 3,436↓2.4% | 3,521↑6.5% | 3,305 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 64↑10.9% | 58↓23.4% | 76↑9.9% | 69↑31.8% | 52 | |
| Selling & Marketing Expenses | 428↑8.9% | 393↓0.4% | 395↑11.9% | 353↑5.1% | 336 | |
| SG&A Expenses | 492↑9.2% | 451↓4.1% | 470↑11.6% | 421↑8.6% | 388 | |
| Other Expenses | 2,387↑8.1% | 2,209↑345.4% | 496↑11023.4% | 4↓55.5% | 10 | |
| Operating Expenses | 2,879↑8.3% | 2,660↑7.5% | 2,475↓2.4% | 2,535↑4.3% | 2,431 | |
| Total Costs & Expenses | 9,287↑8.3% | 8,573↑10.6% | 7,753↑1.6% | 7,630↑6.1% | 7,192 | |
| Operating Results | ||||||
| Operating Income | 908↑3.9% | 873↓9.1% | 961↓4.2% | 1,003↑9.0% | 920 | |
| Depreciation & Amortization | 781↑11.0% | 703↑13.8% | 618↑3.6% | 597↑4.6% | 571 | |
| EBITDA | 1,689↑4.8% | 1,612↓1.9% | 1,644↑3.7% | 1,585↑5.2% | 1,507 | |
| EBIT | 908↓0.1% | 908↓11.6% | 1,027↑3.9% | 988↑5.6% | 936 | |
| Interest & Other Income | ||||||
| Net Interest Income | -92↓41.4% | -65↓148.3% | -26↑61.0% | -67↑11.4% | -76 | |
| Interest Income | 50↓1.9% | 51↓10.6% | 57↑368.5% | 12↑309.5% | 3 | |
| Interest Expense | 142↑22.4% | 116↑39.6% | 83↑4.6% | 79↑0.6% | 79 | |
| Non-Operating Income | -18↑48.3% | -35↑47.1% | -66↓567.6% | 14↑185.5% | -17 | |
| Other Income / Expenses | -62↓59.7% | -39↓131.3% | -17↑74.2% | -65↓3.8% | -62 | |
| Income Before Tax | 846↑1.4% | 835↓11.6% | 944↑0.7% | 938↑9.4% | 857 | |
| Income Tax Expense | 15↑9.8% | 14↓73.2% | 52↑3.0% | 50↑12.0% | 45 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 831↑1.2% | 821↓8.1% | 893↑0.5% | 888↑9.3% | 813 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 831↑1.2% | 821↓8.1% | 893↑0.5% | 888↑9.3% | 813 | |
| Bottom-Line Net Income | 831↑1.2% | 821↓8.1% | 893↑0.5% | 888↑9.3% | 813 | |
| EPS (Basic) | 6.39↑1.3% | 6.31↓8.2% | 6.87↑0.6% | 6.83↑9.3% | 6.25 | |
| EPS (Diluted) | 6.39↑1.3% | 6.31↓8.2% | 6.87↑0.6% | 6.83↑9.3% | 6.25 | |
| Weighted Average Shares | 130↑0.0% | 130↑0.0% | 130↑0.0% | 130↑0.0% | 130 | |
| Weighted Average Diluted Shares | 130↑0.0% | 130↑0.0% | 130↑0.0% | 130↑0.0% | 130 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.